Dialpad Introduces TruCaaS to Business Communications With Launch of Dialpad Meetings for Single, Unified View
13.7.2021 13:10:00 EEST | Business Wire | Press release
Dialpad Inc., the industry leader in AI-powered communication and collaboration, today announced a truly unified approach to communications as a service. With the launch of Dialpad Meetings, the company is bringing its suite of products closer together across both business communications and customer engagement all on one unified, aesthetically cohesive platform with AI at its core.
Dialpad Meetings, formerly known as UberConference, adds new capabilities and establishes the Dialpad cloud communications platform as the one place for a truly unified Communications as a Service (TruCaaS) experience. With a TruCaaS solution delivered through a single pane of glass with an intuitive interface, Dialpad helps customers simplify business collaboration and avoid the growing phenomenon of “app overload.”
“At Dialpad, we believe when the right people come together anything is possible, and we want our brand to reflect this spirit of connection, collaboration and productivity in this new work-from-anywhere world,” said Craig Walker, CEO of Dialpad. “With today’s announcements, we are resetting expectations for communication experiences by building a business communication platform that is more beautiful, accessible, easy to deploy and easy to use — to help businesses of any size start, grow and scale.”
To bring the vision of TruCaaS to life, Dialpad is making the following capabilities available in its single, powerful platform:
-
Dialpad Meetings - The reliable UberConference technology customers know and love with a new look and set of features, including:
- Video conferencing in HD quality for an in-the-room experience
- Real-time Voice Intelligence (Vi™) provides live note-taking and automated transcription analysis, enabling attendees to focus on the conversation and ensure key moments are not missed.
- Start and join Dialpad Meetings from any direct message, group message or channel within the Dialpad app. With Dialpad Meetings natively built into the platform, users are not required to manage multiple tabs or windows.
- Emoji reactions and expressions build social connections with team members and provide feedback in real-time without interruptions.
- Dialpad Channels - With one click, Dialpad Channels offers teams a “light lift” collaboration tool for quick text and/or audio conversations. By providing a space for informal chats, office hours and other water cooler conversations, Dialpad Channels combats video conferencing fatigue and reduces the need for formal 30-minute meetings.
- Mobile screen sharing - Dialpad users can now share their screens on phone calls, whether everyone is a Dialpad user or not. No need to set an official meeting or jump onto a conference call to quickly resolve issues, collaborate on projects or do virtual walkthroughs.
- Global availability - Dialpad Meetings is available through the Dialpad platform with connectivity in 49 countries.
After winning TechCrunch Disrupt NYC in 2012 for UberConference and igniting the work-from-anywhere movement, Dialpad is disrupting an industry built on legacy thinking. As part of this vision and aligned with its TruCaaS approach, Dialpad is launching its Work Beautifully campaign to further support and enable the hybrid workplace.
“Work Beautifully is the big-picture concept that the Dialpad brand and products aspire to. Not only do our talk, messaging, meetings and contact center products work beautifully, they enable others to work beautifully and collaboratively together,” said Morgan Norman, Chief Marketing Officer, Dialpad. “This bold, new visual identity honors Dialpad’s ground-breaking story, its history of innovation in communications, and is deeply rooted in the company’s core values: do the right thing, every voice matters, and experience first.”
The future of work is not restrained by employee or customer location, but is instead borderless; enabled by AI across every experience and seamlessly integrated into how people collaborate and create. Companies that embrace work-from-anywhere technology and empower employee and customer experiences with AI have a significant advantage over those that hold tight to outdated modes of communication, collaboration and productivity. Dialpad’s new release with integrated talk, messaging, meetings and contact center — all powered by AI across every experience — arrives at the right moment to help businesses thrive in this post-pandemic, work-from-anywhere world.
“Work Beautifully means simplicity and ease. Dialpad even takes notes and transcribes calls for us. It’s that flow state where work doesn’t feel like work anymore,” said Chad Pierce, Head of Building Technology, WeWork. “Dialpad makes it easy for our teams to stay close, wherever work finds them and frees our teams to collaborate from anywhere on the planet.”
Additional Resources
- Get started with Dialpad today on a 14-day free trial
- Learn more about Dialpad Channels
- Explore the what, how and why of Voice Intelligence in the contact center
- Discover how Dialpad utilizes AI to unify UCaaS and CCaaS
Social Networks:
- Web: https://www.dialpad.com/
- Blog: https://www.dialpad.com/blog/
- Twitter: https://twitter.com/dialpadHQ/
- LinkedIn: https://www.linkedin.com/company/dialpad/
- Facebook: https://www.facebook.com/Dialpadhq/
- Instagram: https://www.instagram.com/Dialpad/
About Dialpad
Dialpad is the leading cloud communications platform for talk, messaging, meetings and contact center in one beautiful app. Dialpad’s platform delivers AI across every employee and customer experience through real-time transcriptions, live agent coaching and sentiment analysis. More than 73,000 of the world’s most innovative businesses, including Domo, Motorola Solutions, Netflix, Splunk, Stripe, T-Mobile, Twitter, Uber and WeWork use Dialpad to connect and collaborate. Dialpad is backed by the world’s leading investors including Amasia, Andreessen Horowitz, Felicis Ventures, GV, ICONIQ Capital, OMERS Growth Equity, Salesforce Ventures, Scale Ventures, Section 32, SoftBank Corp., T-Mobile Ventures and Work-Bench. Visit www.dialpad.com for more information and to request a demo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005389/en/
Contact information
Gavin Gustafson
gavin@dialpad.com
801-255-9915
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
